Pernod et al. found a prevalence of Hp 2-2 twice as high in end-stage renal disease patients with high CVD risk, defined as prior cardiovascular event, diabetes, or dyslipidemia, compared to end-stage renal disease patients with low CVD risk [46]. This evidence concerns the gene HP and metabolic syndrome.